Georgios Schoretsanitis, Dr

  • 5Articles
  • 57.5KReads
  • 2018–2023Active
  • 34Collaborators
  • 216Citations

About

Georgios Schoretsanitis, Dr is affiliated with Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland; Behavioral Health Pavilion, Department of Psychiatry, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, and Department of Psychiatry, Zucker School of Medicine at Northwell/Hofstra, Hempstead, New York; Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Task Force “Therapeutic Drug Monitoring”. Georgios Schoretsanitis has authored or co-authored 5 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2018 and 2023. Their work focuses on Schizophrenia/Schizoaffective Disorders, Depression (MDD), Patient Care, and Psychiatry.

Publications

JCP
Therapeutic Reference Range for Olanzapine
Systematic Review

Therapeutic Reference Range for Olanzapine

July 19, 2023

A therapeutic reference range of 20–40 ng/mL for oral and long-acting injectable olanzapine yields optimal treatment effects in schizophrenia spectrum disorders. Dose reduction is not needed above 40 ng/mL...
, , , et al
JCP
Best Practices for Switching to Clozapine in Patients With Schizophrenia
ASCP Corner

Best Practices for Switching to Clozapine in Patients With Schizophrenia

July 4, 2022

This article provides expert advice on dosage and timing when switching from a prior medication to clozapine in patients with schizophrenia.
,
JCP
Review Article

Outcomes of NMS With Depot Versus Oral Antipsychotics

November 24, 2020

Is the advantage of longer-term medication release with long-acting injectable antipsychotics offset by an increased risk of more prolonged and severe neuroleptic malignant syndrome? This systematic review and pooled...
, , , et al
JCP
Consensus Statement

Consensus on Monitoring Blood Antipsychotic Levels

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
, , , et al
JCP
Original Research

Duloxetine Dosing Strategies and Smoking Status

September 4, 2018

Cigarette smoking is common among individuals depression, and smoking can affect the metabolism of antidepressant medications. Read this article to learn dosing strategies that physicians can employ when treating...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe